Replimune Group, Inc. (REPL): R&D Expense
$221.18M
Year ended 2026-03-31
$212.62M
Trailing 12 months to 2026-06-30
+20.5%
3-year compound annual growth
+31.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $221.18M | +16.8% | 2026-06-29, From 2025-04-01 |
| 2025-03-31 | $189.45M | +8.3% | 2026-06-29, From 2024-04-01 |
| 2024-03-31 | $174.96M | +38.3% | 2025-05-22, From 2023-04-01 |
| 2023-03-31 | $126.53M | +59.1% | 2024-05-16, From 2022-04-01 |
| 2022-03-31 | $79.55M | +40.2% | 2023-05-18, From 2021-04-01 |
| 2021-03-31 | $56.75M | +46.4% | 2022-05-19, From 2020-04-01 |
| 2020-03-31 | $38.76M | +74.8% | 2021-05-20, From 2019-04-01 |
| 2019-03-31 | $22.17M | +64.1% | 2020-06-03, From 2018-04-01 |
| 2018-03-31 | $13.52M | +94.9% | 2020-06-03, From 2017-04-01 |
| 2017-03-31 | $6.94M | n/a | 2019-06-28, From 2016-04-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Replimune Group, Inc. (REPL) | 2026-03-31 | $221.18M | +16.8% |
| Prokidney Corp. (PROK) | 2025-12-31 | $114.12M | -10.6% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $160.64M | +3.4% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $86.40M | +30.9% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $107.83M | -20.1% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $182.37M | +44.6% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $18.67M | -37.4% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
Compare REPL, PROK, PRME, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗